A detailed history of Callan Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Callan Capital, LLC holds 4,440 shares of VRTX stock, worth $2.12 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
4,440
Previous 4,332 2.49%
Holding current value
$2.12 Million
Previous $1.81 Million 14.97%
% of portfolio
0.17%
Previous 0.16%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $42,423 - $52,437
108 Added 2.49%
4,440 $2.08 Million
Q1 2024

May 03, 2024

BUY
$407.69 - $446.08 $57,484 - $62,897
141 Added 3.36%
4,332 $1.81 Million
Q4 2023

Feb 02, 2024

BUY
$343.0 - $410.68 $1.06 Million - $1.27 Million
3,091 Added 281.0%
4,191 $1.71 Million
Q3 2023

Nov 06, 2023

BUY
$338.18 - $362.46 $18,599 - $19,935
55 Added 5.26%
1,100 $382,000
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $298,619 - $335,946
1,045 New
1,045 $301,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $123B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Callan Capital, LLC Portfolio

Follow Callan Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Callan Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Callan Capital, LLC with notifications on news.